Shares of DENTSPLY SIRONA Inc. (NASDAQ:XRAY) have been assigned an average recommendation of “Buy” from the sixteen research firms that are presently covering the firm, Marketbeat reports. Two research analysts have rated the stock with a sell rating, three have given a hold rating and ten have issued a buy rating on the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $69.08.

Several brokerages have recently commented on XRAY. HC Wainwright downgraded DENTSPLY SIRONA from a “buy” rating to a “neutral” rating and set a $68.00 target price on the stock. in a report on Thursday, November 30th. Stifel Nicolaus reaffirmed a “buy” rating on shares of DENTSPLY SIRONA in a report on Thursday, October 19th. TheStreet raised DENTSPLY SIRONA from a “c” rating to a “b-” rating in a report on Friday, November 3rd. Jefferies Group reduced their price objective on DENTSPLY SIRONA from $72.00 to $66.00 and set a “buy” rating on the stock in a report on Wednesday, August 23rd. Finally, Stephens assumed coverage on DENTSPLY SIRONA in a report on Tuesday, November 28th. They set an “overweight” rating and a $75.00 price objective on the stock.

DENTSPLY SIRONA (NASDAQ:XRAY) opened at $66.48 on Friday. The company has a market capitalization of $15,172.85, a P/E ratio of 26.32, a PEG ratio of 2.62 and a beta of 1.31. The company has a quick ratio of 1.59, a current ratio of 2.32 and a debt-to-equity ratio of 0.21. DENTSPLY SIRONA has a 1-year low of $52.53 and a 1-year high of $68.98.

DENTSPLY SIRONA (NASDAQ:XRAY) last announced its earnings results on Friday, November 3rd. The medical instruments supplier reported $0.70 EPS for the quarter, topping the consensus estimate of $0.66 by $0.04. The business had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $978.99 million. DENTSPLY SIRONA had a positive return on equity of 7.56% and a negative net margin of 20.33%. DENTSPLY SIRONA’s revenue was up 5.8% compared to the same quarter last year. During the same period in the previous year, the business earned $0.66 EPS. research analysts anticipate that DENTSPLY SIRONA will post 2.65 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 12th. Shareholders of record on Friday, December 29th will be issued a dividend of $0.0875 per share. This represents a $0.35 annualized dividend and a yield of 0.53%. The ex-dividend date of this dividend is Thursday, December 28th. DENTSPLY SIRONA’s dividend payout ratio is -10.09%.

In other DENTSPLY SIRONA news, Director Francis J. Lunger sold 8,900 shares of the company’s stock in a transaction on Monday, November 13th. The shares were sold at an average price of $65.90, for a total transaction of $586,510.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Mark Thierer bought 77,000 shares of the company’s stock in a transaction on Monday, November 13th. The shares were acquired at an average price of $66.04 per share, with a total value of $5,085,080.00. The disclosure for this purchase can be found here. 1.99% of the stock is currently owned by corporate insiders.

Institutional investors have recently modified their holdings of the business. Veritas Asset Management LLP raised its position in shares of DENTSPLY SIRONA by 2.6% during the 2nd quarter. Veritas Asset Management LLP now owns 6,201,155 shares of the medical instruments supplier’s stock valued at $402,083,000 after acquiring an additional 157,616 shares during the last quarter. Bronfman E.L. Rothschild L.P. raised its position in shares of DENTSPLY SIRONA by 78.7% during the 2nd quarter. Bronfman E.L. Rothschild L.P. now owns 11,886 shares of the medical instruments supplier’s stock valued at $771,000 after acquiring an additional 5,236 shares during the last quarter. Royce & Associates LP raised its position in shares of DENTSPLY SIRONA by 23.4% during the 2nd quarter. Royce & Associates LP now owns 126,650 shares of the medical instruments supplier’s stock valued at $8,212,000 after acquiring an additional 24,000 shares during the last quarter. Delta Lloyd Asset Management N.V. bought a new stake in shares of DENTSPLY SIRONA during the 2nd quarter valued at $15,624,000. Finally, Grandfield & Dodd LLC raised its position in shares of DENTSPLY SIRONA by 1.8% during the 3rd quarter. Grandfield & Dodd LLC now owns 236,109 shares of the medical instruments supplier’s stock valued at $14,122,000 after acquiring an additional 4,140 shares during the last quarter. Institutional investors own 96.58% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “DENTSPLY SIRONA Inc. (XRAY) Receives Average Recommendation of “Buy” from Analysts” was reported by American Banking News and is the sole property of of American Banking News. If you are reading this story on another website, it was illegally stolen and republished in violation of US and international trademark & copyright laws. The correct version of this story can be read at https://www.americanbankingnews.com/2017/12/16/dentsply-sirona-inc-xray-receives-average-recommendation-of-buy-from-analysts.html.

DENTSPLY SIRONA Company Profile

DENTSPLY SIRONA Inc is a manufacturer of professional dental products and technologies. The Company develops, manufactures, and markets solutions offering, including dental and oral health products, as well as other consumable medical devices. It operates through two segments: Dental and Healthcare Consumables, and Technologies.

Analyst Recommendations for DENTSPLY SIRONA (NASDAQ:XRAY)

Receive News & Ratings for DENTSPLY SIRONA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA and related companies with MarketBeat.com's FREE daily email newsletter.